Comparative Pharmacology
Head-to-head clinical analysis: AXITINIB versus VOTRIENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AXITINIB versus VOTRIENT.
AXITINIB vs VOTRIENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Axitinib is a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3). It blocks VEGF-mediated signaling, thereby inhibiting endothelial cell proliferation, migration, and survival, leading to reduced tumor angiogenesis and tumor growth.
Pazopanib is a tyrosine kinase inhibitor that inhibits VEGFR-1, -2, -3, PDGFR-α/β, FGFR-1, -3, and c-Kit.
5 mg orally twice daily (approximately 12 hours apart), with or without food; may increase to 7 mg twice daily or decrease to 3 mg twice daily based on tolerability.
800 mg orally once daily without food (at least 1 hour before or 2 hours after a meal).
None Documented
None Documented
Clinical Note
moderateAxitinib + Digoxin
"Axitinib may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateAxitinib + Digitoxin
"Axitinib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateAxitinib + Deslanoside
"Axitinib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateAxitinib + Acetyldigitoxin
"Axitinib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life: 2.5-6.1 hours; clinical context: supports twice-daily dosing due to rapid clearance
Terminal half-life is 30-35 hours, supporting once-daily dosing. Steady state reached in approximately 2 weeks.
Fecal (41% unchanged, 23% as metabolites); renal (<1% unchanged, 7% as metabolites)
Primarily hepatic metabolism via CYP3A4, with 57% excreted in feces (as metabolites) and 26% in urine (as metabolites). Less than 1% excreted unchanged in urine.
Category C
Category C
VEGF Receptor Tyrosine Kinase Inhibitor
VEGF Receptor Tyrosine Kinase Inhibitor